Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TheraclionFRA:941 -2.34%19 Net Margin % is -895.45% as of Dec. 2025. GuruFocus rates FRA:941 with a GF Score™ of 19/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Theraclion ranks worse than 91.3% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Theraclion's Net Income for the
six
months ended in Dec. 2025 was €-3.15 Mil. Theraclion's Revenue for the
six
months ended in Dec. 2025 was €0.35 Mil. Therefore, Theraclion's net margin for the quarter that ended in Dec. 2025 was -895.45%.
The historical rank and industry rank for Theraclion's Net Margin % or its related term are showing as below:
FRA:941'
s Net Margin % Range Over the Past 10 Years
Min: -693.61 Med: -334.96 Max: -136.26
Current: -479.76
FRA:941's Net Margin % is ranked worse than 91.3% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs FRA:941: -479.76
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Theraclion Net Margin % Related Terms
Theraclion Net Margin % Historical Data
* Premium members only.
The historical data trend for Theraclion's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theraclion's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theraclion Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theraclion's Net Margin % distribution charts can be found below:
* The bar in red indicates where Theraclion's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theraclion (FRA:941) has a Net Margin % of -895.45% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Theraclion and its competitors. According to the industry distribution chart, Theraclion ranks #745 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 91.3%.
Is Theraclion's Net Margin % too high?
Theraclion's current Net Margin % is -895.45%. Based on the distribution chart, Theraclion ranks #745 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Theraclion has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theraclion's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theraclion ranks #745 out of 816 companies for Net Margin %. This places Theraclion in the lower half of its industry. The industry median Net Margin % is 2.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Theraclion and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theraclion's current Net Margin % is -895.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theraclion stock overvalued right now?
Based on GuruFocus' analysis, Theraclion (FRA:941) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €0.54 — trading 125.8% above its estimated fair value. The current Net Margin % is -895.45%. Theraclion's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Theraclion (FRA:941), the current Net Margin % is -895.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theraclion (FRA:941) Overvalued in 2026?
Based on GuruFocus' analysis, Theraclion stock appears to be overvalued.
The current stock price of €0.54 is trading 125.8% above its estimated GF Value™ of €0.24.
GuruFocus considers Theraclion to be Significantly Overvalued.
Key valuation signals for FRA:941:
Net Margin %: -895.45%
GF Value™: €0.24 vs. price of €0.54 (125.8% above fair value)
No single metric tells the full story. See the FRA:941 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theraclion specializes in developing, manufacturing, and marketing echotherapy equipment, associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules. Its products include Sonovein, Echopulse, and Epack.
19GF Score
Get the complete analysis for FRA:941
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:941 has been successfully added to your 
